Response to: Comment on Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al

Yoshiya Tanaka, Koji Oba, Tsutomu Takeuchi

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)E173
JournalAnnals of the rheumatic diseases
Issue number11
Publication statusPublished - 2021 Nov 1


  • DMARDs (biological)
  • rheumatoid arthritis
  • treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this